S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview

About this episode

Nicholas Hornstein discusses advancements in GI oncology and the evolving landscape of colorectal cancer treatment ahead of the 2026 ASCO Annual Meeting.

In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal Cancer Hornstein highlighted the increasing integration of targeted therapies into the first-line setting for patients with colorectal cancer (CRC). For those with BRAF V600E-mutated metastatic disease, data from the phase 3 BREAKWATER trial (NCT04607421) support moving targeted therapy into the first line.1 He noted that initiating these therapies early is critical, as a significant percentage of patients may experience rapid clinical decline and lose the opportunity for second-line treatment if targeted options are delayed. In the HER2-positive space, clinicians currently utilize tucatinib (Tukysa)-based regimens or fam-trastuzumab deruxtecan-nxki (Enhertu). Hornstein also anticipated the arrival of bispecific antibodies, such as zanidatamab-hrii (Ziihera), which are expected to gain…

People in this episode

Guest: Nicholas Hornstein, MD, PhD

Topics covered

• gastrointestinal oncology
• colorectal cancer
• targeted therapies
• clinical trials
• adjuvant therapy
• ASCO preview

Keywords

• gastrointestinal cancers
• targeted therapy
• BRAF V600E
• ctDNA
• pancreatic cancer
• HER2-positive
• bispecific antibodies

Mentioned in this episode

Organizations: CancerNetwork, Donald and Barbara Zucker School of Medicine of Hofstra University, Northwell Health

Products: tucatinib, fam-trastuzumab deruxtecan-nxki, zanidatamab-hrii, ctDNA

Places: Colorectal Cancer, stage II colon cancer

More episodes of Oncology On The Go

• S1 Ep218: Unraveling Key Hematologic Oncology Developments at ASCO 2026 · June 8, 2026 · 24 min
• S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy · June 1, 2026 · 29 min
• S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation · May 25, 2026 · 11 min
• S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors? · May 18, 2026 · 13 min
• S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies? · May 11, 2026 · 12 min
• S1 Ep212: Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer · May 4, 2026 · 20 min